Home > Insider Trading > Filing (0001192482-13-000238)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1361248	Tetralogic Pharmaceuticals Corp	TLOG	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1291262	Md Douglas Reed	C/O Tetralogic Pharmaceuticals Corp 343 Phoenixville Pike Malvern PA 19355		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-12-17	142,857	$7.00	142,857	No	4	P	Indirect	See footnote
Common Stock	Acquisiton	2013-12-17	780,980	$0.00	923,837	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2013-12-17	278,315	$7.00	1,202,152	No	4	C	Indirect	See footnote
Common Stock	Acquisiton	2013-12-17	7,590	$6.40	1,209,742	No	4	X	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	C	Indirect	See footnote
No	4	X	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Convertible Stock	Disposition	2013-12-17	780,980	$0.00	780,980	$0.00
Common Stock	Convertible Notes	Disposition	2013-12-17	278,315	$0.00	278,315	$7.00
Common Stock	Warrants	Disposition	2013-12-17	7,590	$0.00	7,590	$6.40

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	X	Indirect

Footnotes

780,980 shares of Series C Convertible Preferred Stock converted to 780,980 shares of Common Stock at the time of the Company's initial public offering on December 17, 2013.
The Convertible Notes and Accrued Interest automatically converted into Common Stock without payment of further consideration upon the closing of the Issuer's initial public offering, at the initial public offering price of $7.00 per share, which occurred on December 17, 2013.
The warrants were automatically exercised immediately prior to the closing of the Issuer's initial public offering for a number of shares of common stock equal to the warrant amount divided by $6.4022 and net exercised at the initial public offering price of $7.00 per share.
The securities are held of record by Hatteras Venture Partners III, L.P. ("HVPIII") and Hatteras Venture Affiliates, L.P. ("HVAIII"). Hatteras Venture Advisors, LLC is the General Partner of HVPIIII. The reporting person, a partner in HVPIII and HVAIII, has voting and investment power over the shares beneficially owned by HVPIII and HVAIII, and disclaims beneficial ownership of the shares beneficially owned by HVPIII and HVAIII, except to the extent of his pecuniary interest therein.